Sign In
Buy LFVN
Lifevantage Earnings Calls
| Release date | Nov 04, 2025 |
| EPS estimate | $0.170 |
| EPS actual | $0.180 |
| EPS Surprise | 5.88% |
| Revenue estimate | 55.429M |
| Revenue actual | 58.44M |
| Revenue Surprise | 5.43% |
| Release date | Sep 04, 2025 |
| EPS estimate | $0.170 |
| EPS actual | $0.170 |
| Revenue estimate | 57.931M |
| Revenue actual | 55.114M |
| Revenue Surprise | -4.86% |
| Release date | May 06, 2025 |
| EPS estimate | $0.160 |
| EPS actual | $0.260 |
| EPS Surprise | 62.50% |
| Revenue estimate | 56.887M |
| Revenue actual | 58.44M |
| Revenue Surprise | 2.73% |
| Release date | Feb 05, 2025 |
| EPS estimate | $0.130 |
| EPS actual | $0.220 |
| EPS Surprise | 69.23% |
| Revenue estimate | 67.405M |
| Revenue actual | 67.762M |
| Revenue Surprise | 0.529% |
Last 4 Quarters for Lifevantage
Below you can see how LFVN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 05, 2025 |
| Price on release | $22.74 |
| EPS estimate | $0.130 |
| EPS actual | $0.220 |
| EPS surprise | 69.23% |
| Date | Price |
|---|---|
| Jan 30, 2025 | $22.40 |
| Jan 31, 2025 | $21.16 |
| Feb 03, 2025 | $21.63 |
| Feb 04, 2025 | $23.74 |
| Feb 05, 2025 | $22.74 |
| Feb 06, 2025 | $18.99 |
| Feb 07, 2025 | $19.31 |
| Feb 10, 2025 | $20.72 |
| Feb 11, 2025 | $19.68 |
| 4 days before | 1.52% |
| 4 days after | -13.46% |
| On release day | -16.49% |
| Change in period | -12.14% |
| Release date | May 06, 2025 |
| Price on release | $11.97 |
| EPS estimate | $0.160 |
| EPS actual | $0.260 |
| EPS surprise | 62.50% |
| Date | Price |
|---|---|
| Apr 30, 2025 | $12.37 |
| May 01, 2025 | $11.71 |
| May 02, 2025 | $11.91 |
| May 05, 2025 | $11.78 |
| May 06, 2025 | $11.97 |
| May 07, 2025 | $11.18 |
| May 08, 2025 | $11.88 |
| May 09, 2025 | $12.27 |
| May 12, 2025 | $11.86 |
| 4 days before | -3.23% |
| 4 days after | -0.92% |
| On release day | -6.60% |
| Change in period | -4.12% |
| Release date | Sep 04, 2025 |
| Price on release | $13.46 |
| EPS estimate | $0.170 |
| EPS actual | $0.170 |
| Date | Price |
|---|---|
| Aug 28, 2025 | $13.10 |
| Aug 29, 2025 | $13.10 |
| Sep 02, 2025 | $13.55 |
| Sep 03, 2025 | $13.57 |
| Sep 04, 2025 | $13.46 |
| Sep 05, 2025 | $12.11 |
| Sep 08, 2025 | $11.44 |
| Sep 09, 2025 | $11.84 |
| Sep 10, 2025 | $11.23 |
| 4 days before | 2.75% |
| 4 days after | -16.57% |
| On release day | -10.03% |
| Change in period | -14.27% |
| Release date | Nov 04, 2025 |
| Price on release | $7.00 |
| EPS estimate | $0.170 |
| EPS actual | $0.180 |
| EPS surprise | 5.88% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $8.15 |
| Oct 30, 2025 | $8.07 |
| Oct 31, 2025 | $8.19 |
| Nov 03, 2025 | $7.34 |
| Nov 04, 2025 | $7.00 |
| Nov 05, 2025 | $7.31 |
| Nov 06, 2025 | $6.75 |
| Nov 07, 2025 | $7.40 |
| Nov 10, 2025 | $7.26 |
| 4 days before | -14.11% |
| 4 days after | 3.71% |
| On release day | 4.43% |
| Change in period | -10.92% |
Lifevantage Earnings Call Transcript Summary of Q3 2025
LifeVantage reported a strong Q3 FY2025: revenue of $58.4M, up 21% YoY, with the MindBody (MB) GLP-1 system driving U.S. growth (Americas +29.5%) while international markets declined (~-7%). Supply-chain and out-of-stock issues for MB have been resolved. Gross margin improved ~210 bps to 81%, adjusted EBITDA rose 27% YoY to $6.4M (11% margin), and adjusted EPS was $0.26. Active accounts in the Americas grew 17% YoY, subscriptions remain high (historically ~70% of revenue; ~85% of MB sales on subscription in the quarter), and stacking of MB with other products is supporting ARPA and retention. Management continues to roll out LV360 initiatives and the Evolve compensation plan internationally; global MB rollout is ongoing with launches expanding through 2025. The company reiterated adjusted EBITDA and EPS profitability guidance but narrowed revenue outlook to $228M–$235M (midpoint ≈ +16% YoY) to account for international uncertainty. Balance sheet: $22.5M cash, no debt, $5M credit line available, ongoing buybacks (140k shares repurchased YTD) and a $0.045 per-share quarterly dividend ($4.50 appears to be a typo in release—dividend aggregate ~$600k). Key investor takeaways: accelerating U.S. momentum from a differentiated product with strong subscription economics and improving profitability, offset by near-term international variability and conservative revenue assumptions while management completes global MB rollouts and continues consultant education and incentive initiatives.
